Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis

Cancers

Giorgio Valabrega¹  Giulia Scotto¹  Marialuisa Bovetti²  Stefano Cosma²  Andrea Carosso²  Mario Preti²  Dionyssios Katsaros²  Silvia Gemmiti²  Chiara Benedetto²  Fulvio Borella²  Antonio Morrone³  Luca Bertero³  Paola Cassoni³  Alessandro Gambella³ 

[1] Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142 Km 3.95, Candiolo, 10060 Torino, Italy;Department of Surgical Sciences, University of Turin, 10126 Turin, Italy;Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy;

关键词: brain metastases;    ovarian cancer;    BRCA;    treatment;    management;    pathology;   

DOI  :  10.3390/cancers12082156

来源: DOAJ

【 摘 要 】

With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases. BRCA1 and BRCA2 gene mutations, as well as the expression of androgen receptors in the primary tumor, are emerging risk and prognostic factors which could allow one to identify categories of patients at greater risk of BMs, who could benefit from a tailored follow-up. Based on present data, a multidisciplinary approach combining surgery, radiotherapy, and chemotherapy seem to be the best approach for patients with good performance status, although the median overall survival (<1 year) remains largely disappointing. Hopefully, novel therapeutic avenues are being explored, like PARP inhibitors and immunotherapy, based on our improved knowledge regarding tumor biology, but further investigation is warranted.

【 授权许可】

Unknown